From Glucose to Neuroprotection: Exploring Antidiabetic Medications as a Novel Approach to Alzheimer's Disease Treatment.

Autor:	Pandiyan CK; Department of Pharmacy/Pharmacology, Sri Ramaswamy Memorial College of Pharmacy, Sri Ramaswamy Memorial Institute of Science and Technology, Kattankulathur, IND., Manivannan AG; Department of Pharmacy/Pharmacology, Sri Ramaswamy Memorial College of Pharmacy, Sri Ramaswamy Memorial Institute of Science and Technology, Kattankulathur, IND., Jaishankar N; Department of Pharmacy/Pharmacology, Sri Ramaswamy Memorial College of Pharmacy, Sri Ramaswamy Memorial Institute of Science and Technology, Kattankulathur, IND., Vellapandian C; Department of Pharmacy/Pharmacology, Sri Ramaswamy Memorial College of Pharmacy, Sri Ramaswamy Memorial Institute of Science and Technology, Kattankulathur, IND.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Oct 02; Vol. 16 (10), pp. e70710. Date of Electronic Publication: 2024 Oct 02 (Print Publication: 2024).
DOI:	10.7759/cureus.70710
Abstrakt:	Alzheimer's disease (AD) is a major neurological disorder and a leading cause of dementia, which is characterized by progressive cognitive decline. Emerging research highlights the link between AD and type 2 diabetes mellitus (T2DM), suggesting that shared pathophysiological mechanisms, such as insulin resistance, inflammation, and oxidative stress, contribute to both conditions. This connection has led to the concept of type 3 diabetes. Given these overlaps, antidiabetic drugs are being explored for repurposing as potential AD treatments. Intranasal insulin, metformin, thiazolidinediones, and GLP-1 analogs like liraglutide have shown promise in reducing amyloid-beta levels and inflammation, and improving cognitive functions. Despite encouraging preclinical and early clinical results, challenges remain in translating these findings into safe and effective treatments. Continued research could lead to innovative therapies that address both AD and T2DM, offering improved patient outcomes. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Pandiyan et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu